The increase in price target by Citigroup suggests a slightly more optimistic outlook on Arrowhead Pharma's stock, potentially leading to positive investor sentiment in the short term. However, the maintenance of a Neutral rating indicates that the analyst sees limited upside or downside from the current price level.